Do your clients accidentally knock off their continuous glucose monitor (CGM) or complain about how frequently they need to be replaced? If so, did you know there is an implanted CGM option available?
According to the ADA 2025 Standards of Care, CGMs are now the standard of care for individuals using insulin therapy.¹ There are many similarities between the available CGMs, but the Eversense CGM by Senseonics stands out due to some striking differences. As the diabetes education specialist, you can highlight the similarities and differences between CGMs so people can make a personalized and informed decision about which device works best for them.
Get to Know Eversense 365
The Eversense 365 is an implanted CGM (iCGM) used to monitor glucose in individuals 18 or older with diabetes. It is currently the only FDA-approved implantable glucose sensor in the United States. The Eversense system has launched the current 365-day sensor, which was approved for use in October 2024.
This system consists of a small sensor implanted into the subcutaneous tissue of the outer upper arm. A smart transmitter is placed over the inserted sensor to transmit data to a compatible smartphone. Glucose accuracy is similar to other prescription CGMs on the market.²
This system requires initial calibrations when starting a new transmitter. Calibrations must be completed within 36 hours.³
Initial calibration schedule:
- #1 – After the 24-hour warm-up phase
- #2 – 2-12 hours after the first calibration (Glucose readings will then begin to display on the app)
- #3 – 2-12 hours after the second calibration
- #4 – 2-12 hours after the third calibration
Ongoing calibration schedule:
- 1 calibration every 24 hours for 13 days
- 1 weekly calibration for the life of the sensor
Key Components of Eversense 365
The three key components of the Eversense 365 iCGM system are an implantable sensor, a smart transmitter, and a phone app that displays and shares data.
Implantable Sensor
- Sensor has a 365-day lifespan.
- Subcutaneous placement by trained provider.
- Sensor precautions:
- Do not inject insulin or insert an insulin pump infusion site within 4 inches of the iCGM sensor.
- Do not use lithotripsy, diathermy, electrocautery, or receive vaccinations near the inserted sensor, as this may cause damage to the sensor.
- The sensor can be worn in an MRI under specific conditions (see Eversense 365 Glucose Monitoring System User Guide for more information).
Smart Transmitter
- The transmitter is removable and rechargeable.
- Glucose data is transmitted every 5 minutes to the Eversense 365 app after the second calibration.
- Creates vibration alerts for high and low glucose readings.
- The transmitter must be removed before MRI, CT, or x-ray.
Mobile App & Data Sharing:
- Eversense 365 app displays real-time glucose trends.
- The app allows individuals to share glucose data with family, friends, and healthcare providers.
Eversense 365 Eligibility, Benefits, & Risks
The Everesense iCGM is approved for adults aged 18 and older with diabetes. This is available by prescription only. Medicare coverage for CGM requires a diagnosis of diabetes and being treated with insulin, or having two or more level 2 hypoglycemic episodes (<54 mg/dL).⁴ Coverage with commercial insurance varies, and Medicaid coverage varies from state to state.
Eversense 365 Benefits
- Decreased CGM adhesive allergies
- The silicone-based adhesive can result in fewer skin reactions.
- Less frequent sensor changes
- The sensor is placed only once a year.
- Decreased wasted sensors falling off or failing early
- The transmitter is removable and can be replaced easily if knocked off.
- Decreased rate of compression lows
- Fewer compression lows have been noted⁵
- No worry about vitamin C or acetaminophen interfering with CGM readings
- These do not interfere with iCGM glucose readings like with other CGMs.
Contraindications & Precautions
- Do not use in individuals with known allergy to:
-dexamethasone or dexamethasone acetate
-any component of the sensor, transmitter, or adhesive - Mannitol or sorbitol (intravenous, irrigation, or peritoneal dialysis solution, but not sorbitol in the diet) can cause falsely elevated glucose levels.
- The tetracycline antibiotic class can cause falsely low glucose readings
- Always check fingerstick blood glucose for very high or very low glucose readings before making a treatment decision
- The system has not been tested on:
-Those who are pregnant
-Those under 18 years old
-Those taking certain medications: chemotherapy, anticoagulant therapy, or immunosuppressive therapy
-Those with active implantable devices (such as a cardiac defibrillator)³
Role of the Diabetes Education Specialists
Diabetes care and education specialists (DCES) are an essential source of information for those living with diabetes to help achieve glycemic goals with a personalized approach to technology. Individualized education and training on the Eversense 365 iCGM ensure the proper use of the system, including calibration and interpretation of the glucose data. Understanding the details of the Eversense 365 allows the DCES to efficiently help troubleshoot problems, leading to long-term adherence and maximizing the benefits of an iCGM to improve diabetes outcomes.
Ready for a closer look at how technology integrates into successful diabetes outcomes? Check out the 2025 Virtual Diabetes Ed Training Conference for technology updates and more!
References
- American Diabetes Association Professional Practice Committee. (2025). Diabetes technology: Standards of care in diabetes – 2025. Diabetes Care, 48 (supplement 1), S146-S166. https://doi.org/10.2337/dc25-S007
- Danatech. (n.d.). Find & compare continuous glucose monitors. https://www.adces.org/education/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/view-compare-cgms
- Senseonics. (2025) Eversense 365 Continuous Glucose Monitoring System User Guide.https://www.eversensecgm.com/user-guides/
- American Diabetes Association. (n.d.). FAQs on CGM coverage criteria changes in Medicare. https://diabetes.org/advocacy/cgm-continuous-glucose-monitors/faqs-medicare-coverage#:~:text=Medicare%20now%20allows%20people%20to,day%20to%20access%20a%20CGM.
- Christiansen, M. P., Klaff, L. J., Brazg, R., Chang, A. R., Levy, C. J., Lam, D., Denham, D. S., Atiee, G., Bode, B. W., Walters, S. J., Kelley, L., & Bailey, T. S. (2018). A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technology & Therapeutics, 20(3), 197. https://pmc.ncbi.nlm.nih.gov/articles/PMC5867508/
Learn more about leveraging CGM Data
ReVive 5 Diabetes Training Program
This unique training program is led by two experts in the field, Larry Fisher, PhD and Susan Guzman, PhD. Join us live on July 15th and July 22nd, 2025 for this one-of-a-kind training that will transform your approach to caring for people with diabetes.
In the first half, you will learn how to identify distress and provide therapeutic coaching and care based on the results. Coach Beverly leads the second half, walking participants through the 5 step process of reviewing glucose data and addressing distress.
The ADA Standards of Care now recommends annual screening for diabetes distress. If you are wondering how to screen for distress and tailor education based on the results, we encourage you to join this unique training program.
![](/wp-content/uploads/2023/01/insta-png-v5.png")
